Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) is dedicated to supporting innovative projects and programs that enhance the knowledge and understanding of diseases and technological advancements. Their commitment is toward advancing scientific awareness and technologies for public health and welfare in various therapeutic areas of interest. They aim to further scientific progress while ensuring that the projects they support maintain independent control over their goals and dissemination of knowledge.
The grant programs from Boehringer Ingelheim focus on supporting scientific research that has the potential to improve patient outcomes and the quality of healthcare. This includes Investigator-Initiated Studies (IIS) and External Collaborative Research (ECR). IIS grants are designed for proof of concept or exploratory studies that are not registrational, covering fair market value costs excluding direct salary support for Principal Investigators. Boehringer Ingelheim may offer financial support and/or drug supplies for approved IIS but does not act as the regulatory sponsor. ECR grants are available to qualified academic and community-based scientists or consortia looking to propose a study and collaborate with Boehringer Ingelheim on developing protocols, analysis, and publication of results, potentially offering drug and/or financial support but not serving as the Regulatory Sponsor. Both programs encourage applications whose research interests align with Boehringer Ingelheim’s, though other innovative research interests may also be considered.